PMID- 32552226
OWN - NLM
STAT- MEDLINE
DCOM- 20211214
LR  - 20220424
IS  - 1532-4311 (Electronic)
IS  - 0882-0139 (Linking)
VI  - 50
IP  - 5
DP  - 2021 Jul
TI  - Relationship between the Monocyte Chemo-attractant Protein-1 gene rs1024611 A>G 
      Polymorphism and Cancer Susceptibility: A Meta-analysis Involving 14,617 
      Subjects.
PG  - 461-477
LID - 10.1080/08820139.2020.1776726 [doi]
AB  - Inflammatory and inducible chemokines are the hallmarks of malignancy. Monocyte 
      chemo-attractant protein-1 (MCP-1) is a crucial chemokine implicated in infection 
      and inflammation. Methods: We performed an updated meta-analysis of thirty 
      independent case-control studies with 6,777 cancer cases and 7,840 controls to 
      determine if the MCP-1 gene rs1024611 A > G variant is associated with the risk 
      of cancer. Results: The G allele carriers of rs1024611 in the MCP-1 gene might 
      have a null association with cancer risk in overall comparison. In a subgroup 
      analysis by ethnicity, we identified a marked association between the MCP-1 G 
      allele rs1024611 polymorphism and cancer risk in the Caucasian populations (GG 
      vs. AA: OR = 1.72, 95% CI, 1.12-2.64, P = .013, and GG vs. AG/AA: OR = 1.82, 95% 
      CI, 1.19-2.78, P = .006). The potential bias in literature selection was 
      witnessed in this meta-analysis (G vs. A: P (Begg's) =  0.187, 
      P(Egger's) =  0.049; and GG/GA vs. AA: P (Begg's) =  0.069, P(Egger's) =  0.024). 
      The adjusted ORs and CIs of the nonparametric "trim-and-fill" method demonstrated 
      the reliability of these findings. The outcome of heterogeneity analysis 
      indicated that heterogeneity might be due to small sample sizes (<1000 subjects), 
      cancer types (bladder cancer, other cancers), ethnicity (Asians), and 
      population-based studies. However, the sensitivity analysis validated the 
      reliability of the findings. Conclusion: In conclusion, this updated 
      meta-analysis showed that the G carrier of the MCP-1 gene rs1024611 is associated 
      with susceptibility to cancer in Caucasian.
FAU - Chen, Zhan
AU  - Chen Z
AD  - Department of Cardiothoracic Surgery, Zhuhai People's Hospital, Zhuhai Hospital 
      Affiliated with Jinan University, Zhuhai, China.
FAU - Yin, Shiping
AU  - Yin S
AD  - Physical Examination Center, Affiliated People's Hospital of Jiangsu University, 
      Zhenjiang, Jiangsu Province, China.
FAU - Zheng, Liang
AU  - Zheng L
AD  - Department of Thoracic Surgery, The Third Affiliated Hospital of Soochow 
      University, Changzhou, Jiangsu Province, China.
FAU - Tang, Weifeng
AU  - Tang W
AD  - Department of Thoracic Surgery, Fujian Medical University Union Hospital, Fuzhou, 
      Fujian Province, China.
FAU - Kang, Mingqiang
AU  - Kang M
AD  - Department of Thoracic Surgery, Fujian Medical University Union Hospital, Fuzhou, 
      Fujian Province, China.
AD  - Key Laboratory of Ministry of Education for Gastrointestinal Cancer, Fujian 
      Medical University, Fuzhou, Fujian Province, China.
AD  - Fujian Key Laboratory of Tumor Microbiology, Fujian Medical University, Fuzhou, 
      Fujian Province, China.
FAU - Wei, Wei
AU  - Wei W
AD  - Department of Cardiothoracic Surgery, Zhuhai People's Hospital, Zhuhai Hospital 
      Affiliated with Jinan University, Zhuhai, China.
FAU - Sui, Kang
AU  - Sui K
AD  - Department of Cardiothoracic Surgery, Zhuhai People's Hospital, Zhuhai Hospital 
      Affiliated with Jinan University, Zhuhai, China.
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
DEP - 20200618
PL  - England
TA  - Immunol Invest
JT  - Immunological investigations
JID - 8504629
RN  - 0 (CCL2 protein, human)
RN  - 0 (Chemokine CCL2)
SB  - IM
MH  - Chemokine CCL2/*genetics
MH  - Genetic Predisposition to Disease
MH  - Humans
MH  - Neoplasms/*genetics
MH  - Polymorphism, Single Nucleotide
MH  - *Population Groups
MH  - Risk
OTO - NOTNLM
OT  - Monocyte chemoattractant proteins
OT  - meta-analysis
OT  - neoplasm
OT  - polymorphism
OT  - risk factors
EDAT- 2020/06/20 06:00
MHDA- 2021/12/15 06:00
CRDT- 2020/06/20 06:00
PHST- 2020/06/20 06:00 [pubmed]
PHST- 2021/12/15 06:00 [medline]
PHST- 2020/06/20 06:00 [entrez]
AID - 10.1080/08820139.2020.1776726 [doi]
PST - ppublish
SO  - Immunol Invest. 2021 Jul;50(5):461-477. doi: 10.1080/08820139.2020.1776726. Epub 
      2020 Jun 18.